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Background and PurposezzLevetiracetam (LEV) is a new antiepileptic drug that has been 
found to be effective as an adjunctive therapy for uncontrolled partial seizures. However, the re-
sults of several studies suggested that LEV has negative psychotropic effects, including irritabil-
ity, aggressiveness, suicidality, and mood disorders. We investigated the impact of adjunctive 
LEV on psychiatric symptoms and quality of life (QOL) in patients with drug-refractory epilep-
sy (DRE) and determined the risk factors provoking psychiatric adverse events. 
MethodszzA 24-week, prospective, open-label study was conducted. At enrollment, we inter-
viewed patients and reviewed their medical charts to collect demographic and clinical informa-
tion. They were asked to complete self-report health questionnaires designed to measure various 
psychiatric symptoms and QOL at enrollment and 24 weeks later. 
ResultszzSeventy-one patients were included in the study, 12 patients (16.9%) of whom dis-
continued LEV therapy due to serious adverse events including suicidality. The risk factor for 
premature withdrawal was a previous history of psychiatric diseases (odds ratio 4.59; 95% con-
fidence interval, 1.22-17.32). LEV intake resulted in significant improvements in Beck Anxiety 
Inventory score (p<0.01) and some domains of the Symptom Checklist-90-Revised, such as so-
matization (p<0.05), obsessive-compulsiveness (p<0.05), depression (p<0.05), and anxiety (p< 
0.05). These improvements were not related to the occurrence of seizure freedom. The Quality of 
Life in Epilepsy Inventory-31 overall score and subscale scores, such as seizure worry (p<0.01), 
overall QOL (p<0.05), emotional well-being (p<0.05), energy-fatigue (p<0.05), and social func-
tion (p<0.05), also improved. 
ConclusionszzAdjunctive LEV in patients with DRE is likely to improve psychiatric symp-
toms and QOL. Clinicians should be well aware of the psychiatric histories of patients to pre-
vent them from developing serious adverse events related to LEV.  
J Clin Neurol 2011;7:128-136
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Introduction
The impact of psychiatric problems in people with epilepsy 
(PWE) has been neglected for a long time. However, recent 
studies have demonstrated that comorbid psychiatric disor-
ders, and especially depression, can impair the quality of life 
(QOL), increase the suicidal risk, and affect the cost and use 
of medical services.
1-3 Psychopathology in PWE has a multi-
factorial etiology including patient-related, epilepsy-related, 
and antiepileptic drug (AED)-related factors.
4 Drug-refractory 
epilepsy (DRE), which is thought to be the most serious epi-
leptic event accompanying uncontrolled seizures despite ade-
quate trials of AEDs,
5 elicits significant psychiatric problems 
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including increased suicidal risk
6 and develops poor QOL.
1,7 
AEDs are also associated with several mood and behavior 
problems due to the mechanisms of action underlying their 
antiepileptic activity. AEDs can be divided into two categories 
according to their psychotropic properties:8 i) sedating or 
GABA (γ-aminobutyric acid)ergic drugs and ii) activating or 
antiglutamatergic drugs. This classification is straightforward, 
but can only partly explain the psychiatric adverse events of 
AEDs, which are also associated with indirect mechanisms 
due to their interaction with the underlying epileptic process.
4 
Levetiracetam (LEV) is a new AED that has been found to 
be effective as adjunctive therapy for uncontrolled partial sei-
zures with and without secondary generalization.
9,10 LEV was 
introduced into the South Korean market in January 2007, and 
approved as an add-on therapy for partial seizures. LEV has a 
favorable pharmacokinetic profile and a low incidence of ad-
verse events or interactions with other AEDs.
11 Central nerve 
system (CNS)-related adverse events such as somnolence, 
lethargy, dizziness, headache, and tiredness were common, but 
also transient and dose-related.
9,10 Since the mechanism under-
lying the action of LEV is unique and related to modulation of 
synaptic vesicle glycoprotein 2A,
12 its precise psychotropic ef-
fect has not been elucidated. Preclinical studies using animal 
models of depression, anxiety, and mania have provided evi-
dence for LEV as a mood stabilizer.
13 In a systematic review 
using a human trial database, the incidence of behavioral ad-
verse events was lower for LEV than those reported for some 
other AEDs, despite the relative higher frequency compared 
with placebo.
14 Adjunctive LEV therapy in patients with DRE 
had a more favorable psychiatric impact than an add-on prega-
balin in a comparative short-term study.
15 An uncontrolled stu-
dy found that depressive and anxiety symptoms in patients 
with DRE were significantly improved in a 3-months add-on 
trial of LEV.
16 In an open-label multicenter study, LEV mono- 
and add-on therapy possibly contributed to improve psychiat-
ric symptoms such as interpersonal sensitivity and paranoid 
ideation, while simultaneously reducing seizure frequency, ul-
timately ameliorating QOL.
17
Despite the favorable outcomes of LEV in PWE, several 
studies have suggested that this drug has negative psychotro-
pic effects, including irritability, aggressiveness, suicidality, 
mood disorders, and other psychiatric symptoms in both chil-
dren and adult patients.
18-26 The risk factors of the development 
of psychiatric adverse events were poor seizure control, men-
tal retardation, organic psychosyndrome, impulsivity, previous 
psychiatric or febrile convulsion history, and familial predis-
position.
19,22,23 Comorbid psychiatric symptoms in PWE are 
known to be the strongest predictor of QOL, irrespective of 
seizure control,
1 and theses symptoms can sometimes push 
patients towards suicidal behavior.
21,26 It is therefore very im-
portant to determine the psychotropic effects of AEDs, regard-
less of their excellent efficacy on seizure control, to prevent 
them from provoking harmful effects. Unfortunately, no previ-
ous studies have evaluated the psychotropic effects of LEV in 
Korean PWE. Thus, we investigated the psychotropic effects 
of LEV in patients with DRE, who are more likely to have psy-
chiatric problems and a poor QOL than those who are seizure 
free, and elucidated the risk factors for provoking psychiatric 
adverse events. 
Methods
Subjects
This study included consecutive PWE who took AEDs and at-
tended our epilepsy clinic from February 1, 2009, to June 30, 
2010. We selected patients who had DRE, which was defined 
as a failure of adequate trials of two AEDs, at least one seizure 
per month for 18 months, and no seizure-free periods longer 
than 3 months.
27 We excluded patients younger than 18 years, 
those who had undergone epilepsy surgery, and those with se-
vere medical and psychiatric disorders, mental retardation (Ko-
rean Wechsler Adult Intelligence Scale IQ <70),
28 or alcohol 
or drug abuse who were unable to undergo various psychomet-
ric tests and QOL measurement. 
Study design
This study was approved by the institutional review board of 
Kyungpook National University Hospital. At enrollment, all 
subjects gave their informed consent to participate, and were 
then asked to complete reliable and validated self-reported 
health questionnaires, including psychometric tests such as the 
Korean versions of the Beck Depression Inventory (BDI),
29 
Beck Anxiety Inventory (BAI),
30 Symptom Checklist-90-Re-
vised (SCL-90-R),
31 Scale for Suicide Ideation-Beck (SSI-
Beck),
32 and Quality of Life in Epilepsy Inventory-31 (QO-
LIE-31).
33 Each patient was interviewed by trained epilepto-
logists (S.P. and J.L.), who also reviewed the medical charts to 
collect demographic and clinical information into the comput-
erized database. Information collected included seizure type, 
age at onset, duration and etiology of the epilepsy, duration of 
AED intake, number of AEDs, concurrent medical illnesses, 
history of febrile convulsion, family history of epilepsy, and 
MRI abnormalities. The etiology of epilepsy was determined 
by the clinical history, neurological examination, and electro-
encephalography and MRI findings. 
A 24-week, prospective, open-label study was conducted to 
evaluate the psychotropic effect of LEV in patients with DRE. 
The study consisted of a 12-week baseline phase, followed by 
a 4-week titration phase and then a 20-week maintenance ph-
ase. We added LEV to each patient’s current AED regimen. Psychiatric Symptoms and QOL in DRE Receiving LEV
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Patients were asked to visit every 2 weeks during the first 4 
weeks after the LEV intake, and then every 4 weeks thereafter. 
We titrated LEV as follows: 250 mg twice daily for the first 2 
weeks, and 500 mg twice daily (an initial target dose) for the 
third and fourth weeks. Thereafter, the dose regimens were ad-
justed individually based on the investigator’s clinical judg-
ment regarding the patient’s clinical response and tolerability, 
to obtain the best seizure control and tolerability. The LEV 
dosage was titrated up to 3,000 mg/day if the attacks had not 
subsided. Patients were given the opportunity to discontinue 
treatment if they wanted to drop out of the study due to the 
lack of efficacy or intolerable adverse events, or if their physi-
cians observed serious adverse events related to LEV. 
The dose of other AEDs must have been stable for 12 weeks 
prior to entry and remained stable throughout the study. Addi-
tional medication could be prescribed for the well-being of the 
patients; however, medications (other than AEDs) affecting 
CNS were avoided unless the patient had been on a stable dose 
for at least the previous 6-months before entry into the study. 
Concomitant medication remained at the same stable dose 
throughout the study. Seizure occurrence was recorded at base-
line and on completion of the study. The frequency of adverse 
events was assessed through patient perceptions and clinical 
observations at 4 and 24 weeks after the initiation of the study. 
We initially examined the risk factors of premature with-
drawal from the study due to serious adverse events by com-
paring demographic and clinical variables between patients 
with premature withdrawal and those who completed the study. 
Psychometric tests and QOLIE-31 scores were evaluated at 
baseline and on completion of the study. We investigated dif-
ferences in these measurements between pre- and post-LEV 
trials to investigate the psychotropic effects of LEV and to de-
termine the impact of LEV on QOL. If negative psychotropic 
effects were observed, we also determined the risk factors 
thereof.
Efficacy and safety measurements
Efficacy end points were based on the frequency of seizures 
during the final 12 weeks of treatment compared with the 12 
weeks baseline period. The primary efficacy variables were 
the incidence of ≥50% and ≥75% reduction in seizure fre-
quency during the treatment period compared with baseline 
seizure frequency, and seizure freedom, defined as a 100% re-
duction in seizure frequency. Seizure frequency was obtained 
from self-reported seizure diaries and physician’s query. At 
each visit, the investigator classified the reported seizures ac-
cording to the criteria of the Commission on Classification and 
Terminology of the International League Against Epilepsy.
34
Information regarding adverse events was identified at each 
visit using a nonstructured interview and by clinical observa-
tion. An adverse event was defined as any diagnosis or symp-
tom that occurred during the treatment period, regardless of its 
relationship to LEV. We evaluated adverse events twice, at 4 
and 24 weeks, and compared the frequency of adverse events 
between theses two epochs. 
Psychometric tests
Beck	Depression	Inventory	and	Beck	Anxiety	Inventory
The BDI is the most commonly used self-rating scale for de-
pression.
29 It comprises 21 items, each of which is scored on a 
scale of 0-3 according to how the patient feels at the current 
time. The BAI is a 21-item self-reported measure of anxiety 
severity,
30 wherein the respondent is asked to rate how much 
he or she has been bothered by each symptom during the pre-
vious week. The answers are also scored on a 4-point scale 
ranging from 0 to 3. The Cronbach’s α coefficients were 0.89 
for BDI and 0.91 for BAI.
Symptom	Checklist-90-Revised	
The SCL-90-R is a self-rated scale that has 9 psychiatric 
symptom domains, comprising 90 items with a rating scale 
with 5 degrees of severity.
31 The psychiatric domains evaluat-
ed are somatization (α=0.72), obsessive-compulsiveness (α= 
0.83), interpersonal sensitivity (α=0.84), depression (α=0.89), 
anxiety (α=0.86), hostility (α=0.68), phobic anxiety (α=0.81), 
paranoid ideation (α=0.69), and psychoticism (α=0.67). The 
SCL-90-R index and symptom-scale scores are represented as 
T-scores, with a mean of 50 and a standard deviation of 10. 
Higher T-scores reflect a greater number and/or severity of a 
patient’s self-reported symptoms.
Scale	for	Suicide	Ideation-Beck	
The SSI-Beck is a 19-item, self-reported measure designed to 
evaluate the current severity of a patient’s specific attitudes, 
behaviors, and plans to commit suicide.
32 The items are rated 
on a 3-point scale from 0 to 2. The total score can range from 
0 to 38, with higher scores indicating more intense levels of 
suicidal ideation. The Cronbach’s α coefficients were 0.87.
Quality of Life in Epilepsy Inventory-31
The QOLIE-31 is a 31-item, self-administered questionnaire 
designed specifically to measure the QOL of PWE.
33 It con-
sists of the subscales of seizure worry, overall QOL, emotion-
al well-being, energy-fatigue, cognitive functioning, medica-
tion effects, and social functioning. An overall score for the 
seven subscales was also calculated. Higher QOLIE-31 scores 
are indicative of a better QOL. The Korean version of the QO-
LIE-31 has a Cronbach’s α ranging from 0.69 to 0.86.Lee JJ et al.
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Statistical analysis
Data were analyzed using the Statistical Package for the So-
cial Sciences (SPSS version 17.0, SPSS Inc., Chicago, IL, 
USA). Descriptive statistics are presented as counts, percent-
ages, and mean±standard deviation values. We used the in-
dependent t-test or Fisher’s exact test to compare different 
groups. We calculated the odds ratio to measure the strength 
of any association between two binary data values. Paired t-
test was used to investigate differences in SCL-90-R and QO-
LIE-31 scores between baseline and the completion of the 
study. We applied the Wilcoxon signed-rank test to measure 
differences in the BDI, BAI, and SSI-Beck scores between 
baseline and the completion of the study. The Mann-Whitney 
test and independent t-test was applied to compare the mean 
differences in the psychometric tests scores between patients 
with seizure freedom and those without. The level of statisti-
cal significance was set at p<0.05.
Results
Subjects
One hundred and twenty PWE who met the criteria of DRE 
consecutively visited our epilepsy clinic. Among them, 49 pa-
tients were excluded because they were younger than 18 years 
old (n=4), were mentally retarded (n=27), refused to enroll 
(n=10), suffered from major depressive disorders (n=2), seri-
ous cardiac problems (n=1), systemic cancer (n=1), or chron-
ic alcoholism (n=1), or had undergone epilepsy surgery (n=3), 
Ultimately, 71 patients (59.2% of the original cohort) were in-
cluded in the study. The demographic and clinical characteris-
tics of these patients are summarized in Table 1. Their mean 
age was 35.4 years, the mean age at onset was 21.8 years, the 
mean duration of epilepsy was 13.6 years, and the mean num-
ber of seizures during the 12-week baseline period was 14.3. 
Almost all of the patients had partial seizures, and temporal 
lobe epilepsy was the predominant epileptic syndrome. A pre-
vious history of psychiatric diseases was noted in 26 of the 71 
patients (36.6%). Twelve patients had been treated for major 
depressive disorders, 8 for general anxiety disorders, 6 for 
dysthymia, 3 for social phobia, 2 for agoraphobia, 2 for obses-
sive-compulsive disorder, 2 for adjustment disorder, 1 for 
hypochondriasis, 1 for personality disorder, and 1 for panic 
disorder. Nine patients (35%) suffered from at least two psy-
chiatric diseases. The mean duration of AEDs intake was 10.6 
years, and the mean number of AEDs at the baseline period 
was 1.9. The most commonly used AED at baseline was car-
bamazepine (44%), followed by lamotrigine (37%), oxcar-
bazepine (27%), topiramate (27%), valproate (17%), zoni-
samide (10%), Phenobarbital (8%), clonazepam (6%), phe-
nytoin (6%), gabapentin (4%), and vigabatrin (1%). 
Of the 71 enrolled patients, 56 (78.9%) completed the study. 
Fifteen discontinued the study due to adverse events (n=12) or 
a lack of efficacy (n=3). The mean daily dose of LEV at 24 
weeks was 2017.9 mg (ranging from 1,000 to 3,000 mg).
Efficacy and safety
At the end of the 24 weeks of LEV treatment, 18 of the 56 pa-
tients (32.1%) had achieved seizure freedom. A reduction in 
seizure frequency of at least 75% was noted in 22 of the 56 pa-
tients (39.3%), and a reduction of at least 50% was manifested 
in 33 (58.9%). The mean daily dose of LEV inducing seizure 
freedom, which occurred at 6 weeks after the initiation of LEV 
was 1,208 mg/day.
Twelve patients (16.9%) discontinued LEV due to serious 
adverse events within 4 weeks of commencing the medication. 
These adverse events were CNS-related symptoms (n=8), 
headache or other pains (n=6), psychiatric symptoms (n=5), 
gastrointestinal problems (n=5), memory or language prob-
lem (n=4), visual problems (n=2), and skin rash (n=1). Psy-
chiatric symptoms related to premature withdrawal were ner-
vousness, irritability, anxiety, hostility, depression, and suicidal 
ideation or attempt. Two patients felt an uncontrollable sui-
cidal ideation and attempted suicide with a LEV intake 500 
and 1,000 mg/day respectively, and one patient only felt sui-
cidal ideation with a LEV intake 1,000 mg/day. One patient 
who attempted suicide was seizure free for the initial 2 weeks 
of medication, but the others experienced no changes in their 
seizure frequency. These patients concomitantly complained 
of CNS-related adverse events due to LEV, such as somno-
Table 1. Demographic and clinical characteristics of patients
Characteristics  Patients (n=71) 
Age, y, mean (SD)  35.4 (11.0) 
Gender, % male  54 
Education, y, mean (SD)  12.7 (2.5) 
IQ score, mean (SD)  98.7 (12.1) 
Seizure type, partial, no. (%)     67 (94) 
Etiology, symptomatic, no. (%)     36 (51) 
Syndrome, temporal lobe epilepsy, no. (%)     48 (68) 
Age at onset, y, mean (SD)  21.8 (11.5) 
Duration of epilepsy, y, mean (SD)  13.6 (8.8) 
Baseline seizure frequency, /12 weeks,  
  mean (SD) 
14.3 (19.6) 
Concomitant medical diseases, no. (%)       4 (6) 
Previous history of psychiatric diseases,  
  no. (%) 
   26 (37) 
Previous history of febrile convulsion, no. (%)     13 (18) 
Family history of epilepsy, no. (%)       2 (3) 
MRI abnormality, no. (%)     31 (44) 
Duration of antiepileptic drugs intake, y,  
  mean (SD) 
10.6 (7.9) 
Number of antiepileptic drugs, mean (SD)    1.9 (0.7) Psychiatric Symptoms and QOL in DRE Receiving LEV
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lence, asthenia, and memory problems, and had experienced a 
recent extreme stress. Their seizure type was a complex partial 
seizure evolving to secondary generalization. They all had a 
previous history of psychiatric diseases, and especially depres-
sion, but had only an intermittent, minor experience of suicidal 
ideation; they had never attempted suicide before being medi-
cated with LEV. After the withdrawal of LEV, the suicidal ide-
ation of these patients diminished within 1 week. They were 
transferred to the psychiatric department and administered an-
tidepressants or lamotrigine. The risk factors for the premature 
discontinuation of LEV due to adverse events are listed in Ta-
ble 2. With the exception of a previous history of psychiatric 
diseases, the demographic and clinical variables did not dif-
ferent between the patients who prematurely discontinued 
LEV medication and those who completed the study. The odds 
ratio of history of psychiatric diseases was 4.59 (95% confi-
dence interval: 1.22-17.32).
The adverse events associated with LEV in patients who 
completed the study are listed in Table 3. Adverse events were 
noted in 45 of 56 patients (80.4%) at 4 weeks after the initia-
tion of the study, but only manifested in 21 of 56 patients 
Table 2. Differences of demographic and clinical variables according to the completion of the study
Characteristics Discontinuation of LEV* (n=12) Completion of LEV (n=56) p value
† 
Age, y, mean (SD)    36.2 (12.8)  35.5 (10.9)  0.845 
Sex, % male  67 48 0.344 
Education, y, mean (SD)    12.6 (2.0)  12.8 (2.4)  0.753 
IQ score, mean (SD)  102.1 (11.6)  97.7 (12.4)  0.26 
Seizure type, partial, no. (%)       11 (92)     53 (95)  1 
Etiology, symptomatic, no. (%)         8 (67)     28 (50)  0.353 
Syndrome, TLE, no. (%)         6 (50)     40 (71)  0.182 
Age at onset, y, mean (SD)    23.3 (11.4)  21.8 (11.8)  0.683 
Duration of epilepsy, y, mean (SD)    12.9 (8.3)  13.7 (9.0)  0.792 
Baseline seizure frequency, /12 weeks, mean (SD)    21.3 (25.4)  11.1 (14.8)  0.065 
Concomitant medical diseases, no. (%)         1 (8)       3 (5)  1 
Previous history of psychiatric diseases, no. (%)         8 (67)     17 (30)  0.024 
Previous history of febrile convulsion, no. (%)         1 (8)     12 (21)  0.437 
Family history of epilepsy, no. (%)         1 (8)       1 (2)  0.324 
MRI abnormality, no. (%)         7 (58)     23 (41)  0.344 
Duration of antiepileptic drugs intake, y, mean (SD)    11.2 (8.1)  10.3 (7.7)  0.747 
Number of antiepileptic drugs, mean (SD)      1.8 (0.9)       2 (0.7)  0.216 
*Discontinuation of LEV within 4 weeks due to serious adverse events, 
†Differences of variables between groups were analyzed by the 
independent t-test or Fisher’s exact test.
LEV: levetiracetam, TLE: temporal lobe epilepsy.
Table 3. Adverse events of levetiracetam during the study (n=56)
Adverse event
At 4 weeks, 
n (%) 
At 24 weeks,  
n (%)
p value*
CNS-related 37 (66) 15 (27) <0.001
Psychiatric 20 (36)   8 (14) 0.015
Headache and sensory  
  change
11 (20) 5 (9) 0.176
GI-related 11 (20) 3 (5) 0.042
Cognitive  2 (4) 4 (7) 0.679
Nasopharygeal 2 (4) 0 (0) 0.495
Rash 1 (2) 0 (0) 0.999
Total 45 (80) 21 (38) <0.001
*Fisher’s exact test for comparison of the frequencies of adverse 
events. 
CNS: central nerve system, GI: gastrointestinal.
Table 4. Differences of psychometric test scores between base-
line and the completion of the study
Battery
Baseline  
mean (SD)
At 24 weeks  
mean (SD)
p value*
BDI 16.3 (10.7) 14.9 (10.7) 0.156
BAI 15.8 (11.7) 12.1 (10.6) 0.003
SCL-90-R
Somatization 52.1 (12.7) 49.3 (11.8) 0.013
Obsessive-Compulsive 51.9 (12.7) 48.8 (12.0) 0.021
Interpersonal Sensitivity 51.1 (12.1) 48.9 (13.3) 0.105
Depression 50.9 (12.3) 48.3 (11.8) 0.014
Anxiety 51.8 (12.3) 49.3 (12.4) 0.034
Hostility 50.3 (11.8) 50.7 (11.7) 0.771
Phobic Anxiety 56.6 (14.7) 53.6 (14.9) 0.066
Paranoid Ideation 49.7 (12.3) 48.8 (12.2) 0.498
Psychoticism 51.9 (12.6) 49.7 (13.2) 0.147
SSI-Beck 7.1 (7.5) 6.1 (7.0) 0.070
*Paired t-test for comparison of the scores of SCL-90-R and Wil-
coxon Signed-Rank test for comparison of the scores of BDI, 
BAI, and SSI-Beck.
BDI: Beck Depression Inventory, BAI: Beck Anxiety Inventory, 
SCL-90-R: Symptom Checklist-90-Revised, SSI-Beck: Scale for Sui-
cide Ideation-Beck.Lee JJ et al.
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(37.5%) at the end of the study. The frequency of adverse 
events was significantly decreased during these epochs (p< 
0.001, Fisher’s exact test). Most of the adverse events were 
mild and tolerable. The most common adverse events were re-
lated to the CNS, such as somnolence, asthenia, and dizziness, 
followed by psychiatric problems, such as nervousness, anxi-
ety, and hostility. These adverse events were also significant-
ly decreased at the end of the study (p<0.01 for CNS-related 
side effects and p<0.05 for psychiatric problems; Fisher’s ex-
act test).
Psychometric tests
The BDI, BAI, SCL-90-R, and SSI-Beck scores are compared 
between baseline and the completion of the study in Table 4. 
There were significant improvements in BAI scores (p<0.01) 
and some domains of SCL-90-R, such as somatization (p< 
0.05), obsessive-compulsiveness (p<0.05), depression (p<0.05) 
and anxiety (p<0.05). None of the tests revealed significant 
aggravation of psychiatric symptoms after LEV intake. As 
shown in Table 5, the changes in psychometric test scores rel-
ative to the existence of seizure freedom were minimal, with 
the exception of somatization (p<0.05).
Quality of life
The changes in QOLIE-31 overall and subscale scores between 
baseline and the completion of the study are given in Table 6. 
The overall QOLIE-31 score was significantly increased after 
LEV intake (p<0.01). There were significant improvements in 
QOLIE-31 subscale scores, for seizure worry (p<0.01), overall 
QOL (p<0.05), emotional well-being (p<0.05), energy-fatigue 
(p<0.05), and social function (p<0.05). 
Discussion
This is the first study to evaluate the psychotropic effects of 
LEV as an add-on therapy in Korean patients with DRE. We 
have demonstrated that adjunctive LEV therapy in these pa-
tients not only effectively controlled their seizures, but may 
also have contributed to improvements in their psychiatric 
symptoms and QOL. LEV therapy was discontinued due to 
serious adverse events including suicidality by 16.9% of the 
patient. The risk factor for the premature withdrawal of LEV 
was a previous history of psychiatric diseases. Therefore, cli-
nicians should ask their patients’ psychiatric history before ad-
ministering LEV to prevent the occurrence of serious adverse 
events related to LEV. 
The superiority of the efficacy and tolerability of LEV as an 
add-on therapy in patients with DRE has been well document-
ed. In a meta-analysis of four randomized placebo-controlled 
trials of adjunctive LEV therapy in DRE patients with partial 
onset, indirect comparisons of LEV with other newer AEDs 
manifested that LEV had a favorable responder and/or with-
drawal rate relative to other AEDs with dose used in clinical 
trials.
35 In a prospective, open-label study of adjunctive LEV 
therapy in 92 Korean adults with uncontrolled partial epilepsy, 
≥50% and ≥75% reduction in seizure frequency were experi-
enced by 49.5% and 34%, respectively, and seizure freedom 
was attained in 22.7% during the final 12-weeks.
10 Our data 
revealed more favorable efficacies; ≥50% and ≥75% reduc-
tion in seizure frequency were experienced by 58.9% and 
39.3% of the cohort, respectively, and seizure freedom was ac-
quired in 32.1% during the same period. Regarding the tolera-
bility of LEV, previous studies have found that at least one ad-
Table 5. The comparison of mean differences of psychometric test 
scores between baseline and the completion of the study accord-
ing to the existence of seizure freedom
Battery
Seizure-free 
(n=18) 
mean (SD)
No freedom 
(n=38) 
mean (SD)
p value*
BDI -1.8 (10.9) -1.2 (8.1) 0.795
BAI -5.5 (9.2) -2.7 (8.3) 0.412
SCL-90-R
Somatization -6.0 (7.7) -1.2 (7.9) 0.038
Obsessive-Compulsive -4.6 (9.0) -2.4 (10.2) 0.427
Interpersonal Sensitivity -3.6 (9.6) -1.6 (10.2) 0.487
Depression -4.0 (8.2) -2.0 (7.5) 0.363
Anxiety -5.3 (8.1) -1.2 (8.6) 0.096
Hostility  0.6 (8.9)  0.3 (10.0) 0.900
Phobic Anxiety -6.1 (11.8) -1.6 (12.1) 0.188
Paranoid Ideation -2.7 (7.3)  0.0 (10.2) 0.312
Psychoticism -4.9 (8.7) -1.0 (12.4) 0.228
SSI-Beck -0.2 (5.6) -1.3 (4.2) 0.912
*Independent t-test for comparison of the scores of SCL-90-R 
and Mann-Whitney test for comparison of the scores of BDI, 
BAI, and SSI-Beck.
BDI: Beck Depression Inventory, BAI: Beck Anxiety Inventory, 
SCL-90-R: Symptom Checklist-90-Revised, SSI-Beck: Scale for Sui-
cide Ideation-Beck.
Table 6. Differences of QOLIE-31 scores between baseline and 
the completion of the study
Baseline 
mean (SD)
At 24 weeks 
mean (SD)
p value*
Seizure worry 45.3 (28.3) 57.7 (28.9) 0.001
Overall QOL 48.9 (18.6) 56.2 (17.3) 0.014
Emotional well-being 55.7 (19.7) 63.2 (20.5) 0.018
Energy / Fatigue 40.9 (17.7) 48.9 (22.6) 0.022
Cognitive function 66.4 (23.0) 71.1 (21.4) 0.057
Medication effects 54.4 (26.7) 57.8 (29.6) 0.406
Social function 60.6 (27.3) 68.2 (23.0) 0.024
Overall score 56.1 (17.0) 63.1 (18.5) 0.002
*Paired t-test for comparison.
QOLIE-31: Quality of Life in Epilepsy Inventory-31, QOL: quality 
of life.Psychiatric Symptoms and QOL in DRE Receiving LEV
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verse event manifested in 64-89% of patients.
9,10 A similar 
prevalence of adverse events was found for our patients at 4 
weeks after the initiation of treatment, but the frequency was 
significantly decreased at the end of the study. 
Despite the favorable efficacy and tolerability of adjunctive 
LEV therapy, 16.9% of our patients withdrew prematurely due 
to serious adverse events. The most common adverse event as-
sociated with discontinuation of LEV was CNS-related symp-
toms, followed by headache or other pains, and psychiatric or 
gastrointestinal problems. Psychiatric symptoms related to 
discontinuation of LEV, and which were manifested by 7% 
of our patients, were nervousness, irritability, anxiety, hostility, 
depression, and suicidal ideation or attempt. In placebo-con-
trolled trials investigating the safety profile of LEV in Cauca-
sian DRE patients, 15% of LEV-treated patients and 11.6% of 
placebo-treated patients either withdrew from their respective 
trial or required a dosage reduction.
36-38 The most common 
causes of withdrawal from the trial in the LEV group were 
CNS-related symptoms such as somnolence (4.4%), dizzi-
ness (1.4%), and asthenia (1.3%). Depression and personality 
disorders were also reported as severe adverse events, despite 
the low prevalence (less than 1%). Only 4% of Korean DRE 
patients experienced early withdrawal of LEV, which was due 
to somnolence, headache, abdominal pain, and brain tumor.
10 
Psychiatric adverse events such as abnormal behavior, insom-
nia, anxiety, nervousness, and depression, leading to tempo-
rary discontinuation of LEV, occurred in 5% of patients. 
These results suggest that the likelihood of developing serious 
psychiatric adverse events related to the premature withdrawal 
of LEV is higher in Korean PWE than in Caucasian PWE. 
We have demonstrated that the risk factor for the premature 
withdrawal of LEV due to adverse events in our cohort was a 
previous history of psychiatric diseases. Patients with psychi-
atric history were 4.6 times more likely to withdraw prema-
turely from LEV therapy than those without a psychiatric his-
tory. It is not known why LEV provokes serious adverse events 
in patients with psychiatric history. Furthermore, it has not 
been demonstrated whether this phenomenon is unique to LEV 
or common to many AEDs. Although a positive relationship 
between the psychiatric adverse events associated with LEV 
and a psychiatric history has been reported previously,
19,22,23 
this does not mean that all patients with a psychiatric history 
will discontinue LEV due to the development of psychiatric 
adverse events. Further study is warranted to clarify the rela-
tionship between the premature withdrawal of LEV and psy-
chiatric diseases.
To the best of our knowledge, our finding of suicidality as-
sociated with a specific AED in Korean PWE is a novel one; 3 
of the 71 DRE patients (4.2%) who took LEV manifested sui-
cidality. This cannot be fully explained by forced normaliza-
tion, a phenomenon whereby depressive or psychotic episodes 
develop in patients who become seizure free after having suf-
fered from DRE,
39 because only one patient became seizure 
free after the initiation of LEV. Therefore, we presume that 
LEV may be closely linked to the occurrence of suicidal ide-
ation or behavior. In January 2008, the United State Food and 
Drug Administration issued a safety warning regarding the risk 
of suicidality related to AEDs,
40 which summarized the results 
of a meta-analysis of placebo-controlled clinical trials of 11 
AEDs including LEV. This showed that the risk of the devel-
opment of suicidality was twice as high among patients who 
received AEDs as among those who received the placebo. The 
risk increased soon after the initiation of therapy, persisted 
through week to 24, and was elevated regardless of the type of 
AED received. Our patients also experienced suicidality in the 
early period of a LEV trial. 
There are very few studies in which the risk of suicidality 
associated with AEDs has been examined. Regarding the fre-
quency of suicidality in LEV, only 1 observational study has 
documented that 4 out of 517 Caucasian patients (0.7%) tak-
ing LEV reported suicidal ideation.
21 The frequency of suicid-
ality manifestation was higher in our study, which may be ex-
plained by ethnic differences in the effect of AEDs or the 
frequency of psychiatric histories in the study patients: only 
16% of the Caucasian patients had a psychiatric history,
21 
whereas 37% of our patients manifested a psychiatric history. 
Since we have shown that the existence of a psychiatric histo-
ry may be closely linked to the occurrence of psychiatric ad-
verse events, this may explain the higher frequency of suicid-
ality associated with LEV by our patients. 
We demonstrated that at 24 weeks, adjunctive LEV therapy 
in DRE patients did not aggravate their psychiatric symptoms, 
and rather possibly contributed to improve them. Suicidal ide-
ation also tended to decrease after LEV therapy. These results 
are consistent with those of previous reports.
15-17 Depressive 
and anxiety symptoms and suicidal thoughts were improved 
significantly after LEV intake in an Italian study.
16 Interper-
sonal sensitivity, depression, anxiety and paranoid ideation 
among the domains of SCL-90-R after a LEV trial were ame-
liorated in German and Taiwanese studies.
15,17 In addition, our 
study documented improvements in somatization and obses-
sive-compulsive behavior. Although all of these symptoms 
can be ameliorated by seizure freedom itself rather than the 
psychotropic effects of LEV, with the exception of somatiza-
tion, we found no association between seizure freedom and 
improvement in psychiatric symptoms. Thus, LEV can be 
safely prescribed as a positive psychotropic agent provided the 
physician is aware of the risk factors related to premature with-
drawal of LEV. A previous psychiatric history can be easily de-
tected by simply asking patients or using screening tools to de-Lee JJ et al.
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termine psychiatric symptoms. 
We found that adjunctive LEV therapy significantly im-
proved the patient’s QOL. This result concurs with that of a 
Korean LEV add-on trial.
10 QOL in PWE is known to be im-
proved by complete seizure control.
41 However, since comor-
bid psychiatric symptoms are known to be the strongest pre-
dictor of QOL, irrespective of seizure control,
1 AEDs with a 
negative psychotropic profile may induce poor QOL in a sei-
zure-free state. Therefore, we have shown herein that LEV 
does not have a negative psychotropic profile and may thus 
have a positive effect on QOL.
While our study has documented that LEV is well tolerated, 
with an affirmative result for psychiatric influences, it was 
subject to some methodological limitations. First, since this 
was an open-label study, we cannot exclude the possibility of 
a placebo effect; a placebo-controlled study is thus warranted. 
Second, because the SCL-90-R was not designed to evaluate 
anger, irritability, and aggressiveness, which have been well 
documented in associated with LEV intake,
18,19,22-25 further 
study should thus be conducted to determine the attribution of 
LEV to those symptoms. Third, since our enrolled patients 
were exposed to polytherapy, we cannot exclude the effect of 
a drug interaction between LEV and other AEDs on their psy-
chiatric symptoms. It has been shown that valproate, carbam-
azepine, and lamotrigine are mood stabilizer,
42 and therefore, 
adding LEV to those AEDs may addictively affect the patient’s 
psychiatric symptoms. We were unable to measure this effect 
statistically due to the small number of patients included in 
this study. Further studies enrolling larger numbers of patients 
are needed to elucidate the true effect of LEV on psychiatric 
symptoms.
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